A Glimpse into National Vision Holdings
National Vision Holdings, Inc. EYE finds itself in a position ripe for expansion in the near future. Boosted by the consistent growth of the Owned and Host segments, the company is making significant strides in expanding exam capacity, enhancing recruitment efforts, and implementing remote examination initiatives. Despite these positive developments, the recent termination of the Walmart partnership and the overreliance on vendors serve as potential pitfalls for National Vision.
Over the past year, the Zacks Rank #3 (Hold) stock has shown remarkable growth of 32.6%, overshadowing the industry’s 7.5% rise and the S&P 500 composite’s 31.4% growth. With a market capitalization of $1.78 billion, National Vision boasts a long-term estimated earnings growth of 14.5%, compared to the industry’s 11.5%. Surpassing estimates in the last four quarters, the company has delivered an average earnings surprise of 76.07%. Investing in this optical retailer promises compelling prospects. Let’s explore further.
The Bright Side
The Rise of Owned & Host Segments: National Vision’s Owned and Host sub-segments continue to capture a larger market share. This growth can be attributed to factors like age-related vision deterioration leading to increased purchases of corrective eyewear and a consistent replacement cycle. Notably, America’s Best and Eyeglass World are pivotal in driving revenues for the company.
Image Source: Zacks Investment Research
Expanding its horizons, National Vision opened 70 new stores in 2023, including 16 America’s Best locations and one Eyeglass World store in the fourth quarter alone. Through the integration of remote medicine technology alongside electronic health record systems, the company aims to enhance capacity, streamline in-store operations, and elevate the patient experience.
Promising Future Strategies: In the fiscal year of 2023, National Vision successfully scaled up its exam capacity, achieving a second year of enhanced retention and a record year of recruiting seasoned student hires. The company plans to open an additional 65 to 70 stores in 2024, with a majority falling under the America’s Best brand. Capitalizing on omnichannel capabilities, National Vision is testing consumer-centric programs that span various channels.
Moreover, efforts to optimize store and overall cost structures through digitalization initiatives look promising. The implementation of remote examination services serves as a crucial tool for National Vision amidst the evolving optometric landscape. Cost-saving measures and pricing strategies are projected to yield annual savings of $10 million in 2024. Marketing initiatives are also pivotal in driving foot traffic to National Vision’s stores, considering the infrequent purchase patterns in the optical business.
Healthy Solvency: Exiting the fourth quarter of 2023 with $149.9 million in cash and $10 million in short-term debt, National Vision is in a favorable solvency position. Additionally, the company witnessed a reduction in long-term debt, decreasing from $563 million to $451 million at the end of 2023.
Potential Challenges
Effect of Legacy Business Termination: With the cessation of operating Vision Centers for Walmart as of February 23, 2024, National Vision faces a significant setback. The discontinuation of its AC Lens operations, including the closure of its Ohio distribution center, is expected to impact the company’s revenue, profitability, and cash flows negatively.
Moreover, the transition period and Walmart’s solicitation process may disrupt daily operations, leading to reduced sales and productivity. Retaining staff during this period could incur substantial costs, thereby straining the company’s financials.
Vendor Dependency Concerns: National Vision relies heavily on domestic and international vendors for most of its merchandise. With a limited number of suppliers for eyeglass frames, lenses, and contact lenses, the company faces concentration risk. Notably, 89% of contact lens expenditures in fiscal 2023 were with one vendor, while 92% of lens expenditures were with merely three suppliers.
Projected Outlook
The Zacks Consensus Estimate for National Vision’s 2024 earnings per share (EPS) has decreased from 57 to 54 cents over 30 days. The revenue estimate for 2024 stands at $1.99 billion, indicating a 6.7% decline from the previous year’s figure.
Promising Investment Picks
Exploring other notable stocks in the expansive medical domain, companies like Cardinal Health CAH, Stryker SYK, and DaVita DVA exhibit promising potential for investors.
Cardinal Health holds a Zacks Rank #2 (Buy) and boasts a long-term estimated earnings growth rate of 14.2%. Surpassing estimates consistently, the company has shown a 15.6% average earnings surprise.
Stryker, with a Zacks Rank #2, offers an earnings yield of 3.32% compared to the industry’s -0.12%. Having exceeded estimates in the last four quarters, Stryker delivered a 5.09% average earnings surprise in the latest reported quarter.
DaVita, holding a Zacks Rank #1, showcases a long-term earnings growth rate of 12.1%. Surging 80.8% in the past year, the company has an average earnings surprise of 35.6% over the last four quarters.
5 Stocks Set to Double
Each
The Unveiling of the Ultimate Stock of 2024
A recent revelation labeled one entity the top stock selection with the potential to escalate by over 100% in 2024, marking a notable milestone. Past suggestions have seen skyrocketing gains of +143.0%, +175.9%, +498.3%, and an astonishing +673.0%.
Opportunity Beyond the Radar
With the majority of the stocks featured in the report evading mainstream attention, a lucrative opening to establish initial positions is presented, akin to a hidden treasure trove waiting to be unearthed.
Discover 5 Potential Game-Changers >>
Insightful Analysis on Stryker Corporation (SYK)
Unlocking Potential with DaVita Inc. (DVA)
Exploring Insights on Cardinal Health, Inc. (CAH)
Delving into National Vision Holdings, Inc. (EYE)
For further details, delve into this piece on Zacks.com by clicking here.
Stay in the Loop with Zacks Investment Research
The author’s viewpoints and perspectives expressed herein stand as individual sentiments and not necessarily representative of Nasdaq, Inc.
